Chemplast Sanmar Ltd

- The company is currently executing phase two capex, expected to complete by Q1 FY2025. - They are evaluating new projects on both PVC and custom manufacturing fronts. - The primary preference for capital allocation will be towards custom manufacturing growth. - Expansion opportunities in PVC will be considered once there is comfort around feedstock availability. - No specific mention or plan of new fundraising through debt or equity was stated in the call. - Existing gross debt as of December 31, 2023, is Rs.1,405 Crores; net debt is around Rs.650 Crores. - Management indicated strategic decisions like demerger or separate listing of custom manufacturing will be addressed in the future but no current plan. - Further capex and expansions will be announced after achieving visibility on about 60% of phase two capacity.

- Phase two capex for custom manufacturing and paste PVC is expected to complete by Q1 FY2025. - Post phase two, the company is evaluating multiple projects on both PVC and custom manufacturing fronts. - Capital allocation priority is given to custom manufacturing for growth. - Plans to announce the next phase of expansion after 60% visibility of phase two capacity utilization. - Discussions are ongoing with strategic partners for securing feedstock to enable PVC business expansion. - There is ample space at the current site for further capacity additions beyond phases one and two, allowing future expansions. - The paste PVC project entails an investment of around Rs.360 Crores, expected to augment volumes from Q4 FY2024 onwards.

- Custom manufacturing business is expected to reach around Rs.1,000 Crores in revenue in the next 2-3 years, driven by three signed LOIs and a strong pipeline. - Phase one custom manufacturing capacity will be fully utilized by 2H FY2025, enabling revenue ramp-up. - Specialty paste PVC investment anticipates an asset turn of ~1.2; full utilization of new capacity expected by 2H FY2025, with favorable price corrections potentially enhancing growth. - Together, paste PVC and custom manufacturing expansions are projected to add around Rs.1,500 Crores of turnover over the next couple of years. - Continuous growth in custom manufacturing business expected; future expansion plans contingent on feedstock supply visibility and pipeline commercialization. - The broader PVC industry outlook is positive with expected price and margin recovery over next 2-3 quarters, supported by healthy domestic demand and efforts to address dumping.

- Chemplast Sanmar expects growth from two key investments: specialty paste PVC and custom manufacturing. - For custom manufacturing, the company aims to reach Rs.1,000 Crores in revenue within 2-3 years. - Specialty paste PVC is expected to have an asset turn of around 1.2, with potential to improve if prices normalize. - Full utilization of the new paste PVC capacity is expected by the second half of FY2025. - EBITDA margins for Chemplast Sanmar standalone are expected to sustain around 25% post-recovery; paste PVC business targets 12-15% EBITDA margin with high asset turnover. - Despite current subdued results and margin pressure due to price corrections and dumping impacts, the outlook remains strong with recovery expected over next few quarters. - Continuous expansion in custom manufacturing is envisioned with further phases planned as visibility improves. - Overall, the company anticipates revenue growth driven by volume increases, capacity additions, and margin improvements going forward.

- Chemplast Sanmar has signed three Letters of Intent (LOIs) for custom manufacturing projects. - Two LOIs for intermediates are already commercialized with commercial quantities being booked and sold from the new production block. - The third LOI pertains to an active ingredient currently in the development stage (lab, pilot, customer qualification), taking longer to commercialize. - The company is reasonably confident of reaching Rs. 1,000 Crores revenue in the custom manufacturing business within two to three years, based on these LOIs and the healthy pipeline. - The management does not disclose specific minimum revenue thresholds per molecule but focuses on strategic long-term potential and customer relationships. - There is an evolving scenario with possible postponement or shifting of orders between quarters rather than a decline in volume.